1. Academic Validation
  2. Small molecule inhibition of glycogen synthase I reduces muscle glycogen content and improves biomarkers in a mouse model of Pompe disease

Small molecule inhibition of glycogen synthase I reduces muscle glycogen content and improves biomarkers in a mouse model of Pompe disease

  • Am J Physiol Endocrinol Metab. 2024 Oct 1;327(4):E524-E532. doi: 10.1152/ajpendo.00175.2024.
Rafael Calais Gaspar 1 Ikki Sakuma 1 Ali Nasiri 1 Brandon T Hubbard 2 Traci E LaMoia 2 Brooks P Leitner 2 Samnang Tep 3 Yannan Xi 3 Eric M Green 3 Julie C Ullman 3 Kitt Falk Petersen 1 Gerald I Shulman 1 2 4
Affiliations

Affiliations

  • 1 Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, United States.
  • 2 Department of Cellular & Molecular Physiology, Yale School of Medicine, New Haven, Connecticut, United States.
  • 3 Maze Therapeutics, South San Francisco, California,United States.
  • 4 Howard Hughes Medical Institute, Chevy Chase, Maryland, United States.
Abstract

Pompe disease is a rare genetic disorder caused by a deficiency of the Enzyme acid alpha-glucosidase (GAA). This Enzyme is responsible for breaking down glycogen, leading to the abnormal accumulation of glycogen, which results in progressive muscle weakness and metabolic dysregulation. In this study, we investigated the hypothesis that the small molecule inhibition of glycogen synthase I (GYS1) may reduce muscle glycogen content and improve metabolic dysregulation in a mouse model of Pompe disease. To address this hypothesis, we studied four groups of male mice: a control group of wild-type (WT) B6129SF1/J mice fed either regular chow or a GYS1 inhibitor (MZ-101) diet (WT-GYS1), and Pompe model mice B6;129-Gaatm1Rabn/J fed either regular chow (GAA-KO) or MZ-101 diet (GAA-GYS1) for 7 days. Our findings revealed that GAA-KO mice exhibited abnormal glycogen accumulation in the gastrocnemius, heart, and diaphragm. In contrast, inhibiting GYS1 reduced glycogen levels in all tissues compared with GAA-KO mice. Furthermore, GAA-KO mice displayed reduced spontaneous activity during the dark cycle compared with WT mice, whereas GYS1 inhibition counteracted this effect. Compared with GAA-KO mice, GAA-GYS1 mice exhibited improved glucose tolerance and whole body Insulin sensitivity. These improvements in Insulin sensitivity could be attributed to increased AMP-activated protein kinase phosphorylation in the gastrocnemius of WT-GYS1 and GAA-GYS1 mice. Additionally, the GYS1 inhibitor led to a reduction in the phosphorylation of GSS641 and the LC3 Autophagy marker. Together, our results suggest that targeting GYS1 could serve as a potential strategy for treating glycogen storage disorders and metabolic dysregulation.NEW & NOTEWORTHY We investigated the effects of small molecule inhibition of glycogen synthase I (GYS1) on glucose metabolism in a mouse model of Pompe disease. GYS1 inhibition reduces abnormal glycogen accumulation and molecular biomarkers associated with Pompe disease while also improving glucose intolerance. Our results collectively demonstrate that the GYS1 inhibitor represents a novel approach to substrate reduction therapy for Pompe disease.

Keywords

Pompe disease; muscle glucose metabolism.

Figures
Products